Across multiple subgroups, GLP-1 RA use was consistently associated with reduced risks of hospitalization for coronary artery disease, stroke, heart failure, end-stage kidney disease, sight-threatening retinopathy, and all-cause mortality compared with DPP-4 inhibitor use (Tables S3–S8). The gene discussed is DPP4; the disease is heart failure.